Anzeige
+++Almonty stieg von 0,60 $ auf 30 $: – beginnt hier die nächste Wolfram-Story? – beginnt hier die nächste Wolfram-Story?+++
EQS-News

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion 28.05.2026, 15:35 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Haier Biomedical / Key word(s): Miscellaneous
Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion

28.05.2026 / 15:35 CET/CEST
The issuer is solely responsible for the content of this announcement.


QINGDAO, China, May 28, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) has been named the No. 1 Chinese brand in global life science laboratory equipment sales and No. 1 in overseas sales in the same category, according to 2025 data published by Euromonitor International. The dual ranking places Haier Biomedical at the front of a competitive global field and caps a three-phase international expansion that has delivered a compound annual growth rate exceeding 20 percent.

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor’s Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion

Euromonitor International is one of the world's leading independent market research firms, and its rankings are widely used as benchmarks across global procurement and industry analysis. The two No. 1 positions cover total global sales revenue and overseas sales revenue measured among Chinese-owned brands in the life science laboratory equipment category. The rankings span all global markets, confirming that Haier Biomedical is competing at the highest level against established international manufacturers.

The rankings also carry practical weight for international partners. In a field where equipment reliability, regulatory compliance, and long-term service support are critical to procurement decisions, independent verification of market leadership provides an additional layer of confidence for institutions evaluating suppliers.

Haier Biomedical's international growth began with targeted projects, working directly with organizations including UNICEF and the WHO to solve specific unmet needs and building a leading position in solar-powered vaccine storage. From there, the company scaled its distribution network to cover 160 countries through more than 800 active dealer relationships. The current phase focuses on embedding full operational capabilities in key regions: local warehousing, sales, marketing, product planning, and R&D.

The company now operates overseas R&D centers in the UK, Italy, and Japan, each focused on specific product lines including centrifuges, cold chain and automation storage solutions, incubators, and biosafety cabinets. In the UK and continental Europe, dedicated product specialists in automation and centrifuge technology provide on-site support for GMP compliance, air safety, and sample purification, positioning Haier Biomedical as a laboratory workflow partner. Service standards developed in the US and UK are being replicated across the EU, Southeast Asia, and South Asia.

In Q1 2026, revenue in Germany, Australia, and Canada grew more than 50 percent, while Eastern Europe, South Asia, and Brazil each exceeded 100 percent year-on-year growth, with centrifuges and incubators both doubling in volume. In the pharmaceutical sector, Haier Biomedical is part of the supply chains of multiple leading pharmaceutical companies across key countries including Switzerland, Germany, Denmark, Italy, Singapore, the US, Israel, and India. The company's Ultra Energy series holds all eight top positions in the US Energy Star rankings for its category, making it the bestselling line in that segment.

Looking ahead, Haier Biomedical is set to deepen its localization investments and expand its product range, with the goal of helping global biopharmaceutical and life sciences laboratories improve efficiency and sustainability, as part of the company's vision to lead the world in delivering integrated life sciences tools and intelligent productivity platforms.

For more information, visit https://www.haiermedical.com/.

Photo - https://mma.prnewswire.com/media/2989756/image.jpg 
Logo - https://mma.prnewswire.com/media/2989755/5992025/logo_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/haier-biomedical-achieves-double-no-1-ranking-in-euromonitors-global-life-science-lab-equipment-report-caps-three-phase-global-expansion-302784531.html

rt.gif?NewsItemId=EN70194&Transmission_Id=202605280929PR_NEWS_EURO_ND__EN70194&DateId=20260528


28.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2335356  28.05.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 14:38 Uhr • Artikel • BörsenNEWS.de

Gestern 14:31 Uhr • Artikel • BörsenNEWS.de

Gestern 11:51 Uhr • Artikel • dpa-AFX

Gestern 11:44 Uhr • Artikel • dpa-AFX

Gestern 11:43 Uhr • Artikel • dpa-AFX

Gestern 11:42 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer